This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment
by Zacks Equity Research
Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment have been highlighted in this Screen of The Week article.
Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays
by Zacks Equity Research
Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.
Buy These 4 Low-Beta Stocks to Sail Through Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and AeroVironment (AVAV) are poised to gain.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
Illumina (ILMN) Progresses in Pathogen Genomic Technologies
by Zacks Equity Research
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo
by Zacks Equity Research
Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays
by Zacks Equity Research
LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
Here's Why Investors Should Retain Henry Schein (HSIC) for Now
by Zacks Equity Research
Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.
Integra (IART) Builds Advanced R&D Facility in New Jersey
by Zacks Equity Research
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
by Zacks Equity Research
Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.
Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays
by Zacks Equity Research
Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.
Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?
by Zacks Equity Research
Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.
Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.
Zacks.com featured highlights include Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk
by Zacks Equity Research
Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk are part of the Zacks Screen of the Week article.
Buy These 4 Low-Beta Stocks to Endure Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.
Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust
by Zacks Equity Research
Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.
Penumbra (PEN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 109.09% and 4.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG
Penumbra (PEN) Q4 Earnings Top Estimates, Sales Remain Robust
by Zacks Equity Research
Penumbra's (PEN) sales during the fourth quarter reflect continued demand for its products. The 2023 outlook is encouraging as EPS improves despite macro challenges.
Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.